REMI Quote, Financials, Valuation and Earnings

Milestone Scientific has a net margin of -- compared to Remedent's net margin of -58.13%. Remedent's return on equity of -- beat Milestone Scientific's return on equity of -61.33%.

Remedent has a consensus price target of --, signalling downside risk potential of --. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 123.68%. Given that Milestone Scientific has higher upside potential than Remedent, analysts believe Milestone Scientific is more attractive than Remedent.

Remedent has a beta of 0.007, which suggesting that the stock is 99.252% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.585%.

Remedent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Remedent pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Remedent quarterly revenues are --, which are smaller than Milestone Scientific quarterly revenues of $2.5M. Remedent's net income of -- is lower than Milestone Scientific's net income of -$1.5M. Notably, Remedent's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Remedent is 0.42x versus 8.76x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of -- compared to Remedent's net margin of 2.92%. Remedent's return on equity of -- beat Envista Holdings's return on equity of -34.78%.

Remedent has a consensus price target of --, signalling downside risk potential of --. On the other hand Envista Holdings has an analysts' consensus of $19.13 which suggests that it could grow by 8.73%. Given that Envista Holdings has higher upside potential than Remedent, analysts believe Envista Holdings is more attractive than Remedent.

Remedent has a beta of 0.007, which suggesting that the stock is 99.252% less volatile than S&P 500. In comparison Envista Holdings has a beta of 0.975, suggesting its less volatile than the S&P 500 by 2.472%.

Remedent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Remedent pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Remedent quarterly revenues are --, which are smaller than Envista Holdings quarterly revenues of $616.9M. Remedent's net income of -- is lower than Envista Holdings's net income of $18M. Notably, Remedent's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Remedent is 0.42x versus 1.21x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Solventum has a net margin of -- compared to Remedent's net margin of 1.49%. Remedent's return on equity of -- beat Solventum's return on equity of 9.76%.

Remedent has a consensus price target of --, signalling downside risk potential of --. On the other hand Solventum has an analysts' consensus of $80.14 which suggests that it could grow by 14.11%. Given that Solventum has higher upside potential than Remedent, analysts believe Solventum is more attractive than Remedent.

Remedent has a beta of 0.007, which suggesting that the stock is 99.252% less volatile than S&P 500. In comparison Solventum has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Remedent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Remedent pays -- of its earnings as a dividend. Solventum pays out -- of its earnings as a dividend.

Remedent quarterly revenues are --, which are smaller than Solventum quarterly revenues of $2.1B. Remedent's net income of -- is lower than Solventum's net income of $31M. Notably, Remedent's price-to-earnings ratio is -- while Solventum's PE ratio is 25.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Remedent is 0.42x versus 1.48x for Solventum. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of -- compared to Remedent's net margin of 2.28%. Remedent's return on equity of -- beat Dentsply Sirona's return on equity of -35.57%.

Remedent has a consensus price target of --, signalling downside risk potential of --. On the other hand Dentsply Sirona has an analysts' consensus of $18.07 which suggests that it could grow by 14.3%. Given that Dentsply Sirona has higher upside potential than Remedent, analysts believe Dentsply Sirona is more attractive than Remedent.

Remedent has a beta of 0.007, which suggesting that the stock is 99.252% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.924, suggesting its less volatile than the S&P 500 by 7.642%.

Remedent has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 4.05% to investors and pays a quarterly dividend of $0.16 per share. Remedent pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Remedent quarterly revenues are --, which are smaller than Dentsply Sirona quarterly revenues of $879M. Remedent's net income of -- is lower than Dentsply Sirona's net income of $20M. Notably, Remedent's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Remedent is 0.42x versus 0.86x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.